IMRT for prostate cancer: Preliminary results of toxicity  by Couñago, F. et al.
S96 reports of practical oncology and radiotherapy 1 8 ( 2 0 1 3 ) S91–S103
prostate cancer. The aim of this study is to determine the signiﬁcance of Ki-67 and ERG as a biomarker of patient outcome for
prostate cancer patients treated with radiotherapy.
Methods and materials. Pretreatment archival prostate biopsy tumor tissue was available from 339 stage T1–T4 prostate cancer
patients treatedwith external beam radiotherapy alone or in combinationwith androgendeprivation therapy (ADT) between 2003
and 2005. All patientswere diagnosed by needle biopsy andnone of themhad evidence ofmetastasis. Parafﬁn-embedded prostate
cancer tissue was available in 88/339 patients. Immunohistochemical staining of Ki-67 was used to determine the proliferation
index in each case. The Ki-67 was expressed as a percentage (<3 vs ≥3) of immunoreactive tumor cells to the total counted tumor
cells. ERG-EP11 monoclonal antibody was used to determine the presence of ERG protein. A positive reaction was considered
if the tumor cells showed a nuclear staining to ERG-EP11 antibody. Factors associated to failure, survival and progression were
analysed. Estimates of survival were determined using Kaplan–Meier methods. Unadjusted and adjusted hazard ratios were
calculated using the Cox regression model.
Results. Mean age was 70 years (range 56–84). T1–T2 stage 276 patients (81.5%), T3 61 patients (18%). Initial PSA (ng/ml) was <20,
279 patients (82.4%) and >20, 60 patients (17.6%). Forty-nine percent of patients had Gleason score≥7. Median radiation dose
to prostate was 74Gy. Whole pelvic irradiation was administered in 44%, and 75% received ADT. Expression of Ki-67≥3% was
observed in 64/82 patients (78%) and for ERG+ in 54/82 patients (66%) for the analyzed cohort. Intermediate (Ki-67≥3%, 13/20
pts, 65%, and ERG+, 14/20 pts, 70%), and high-risk (Ki-67≥3%, 45/53 pts, 85%, and ERG+, 35/53 pts, 66%) groups were the highest
expression observed (p<0.05). With a median follow-up of 7.28 years (range 1.4–15 years), the 10-year OS for Ki-67<3 vs Ki-67≥3%
was 89% and 87%, and 93% and 85% for ERG− vs ERG+. The 10-year BRFS for Ki-67<3 vs Ki-67≥3% was 100% and 73% (p 0.06), and
87% and 77% for ERG− vs ERG+. On univariate analysis (for entire cohort, 339 pts), initial psa (p 0.01), Gleason (p 0.001), and nadir
psa post-RT (p 0.001) were signiﬁcantly associated with biochemical failure. Ki-67≥3% was associated with a trend biochemical
failure (p 0.063). Estimates of survival and Cox regression model for 88/339 pts will be presented.
Conclusions. Expression of Ki-67≥3% and ERG+ obtained from pretreatment prostate cancer biopsies could be used as predictor
biomarkers of advanced stages, failure and survival after treatment with radiotherapy.
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Introduction. The intensity-modulated radiotherapy (IMRT) for prostate cancer permits further dose escalation and appears to be
less toxic compared to three-dimensional conformal radiotherapy (3D-CRT).
Objectives. To report the incidence of treatment-related toxicity after IMRT for prostate cancer.
Methods. Between January 2009 and December 2011, 79 patients with prostate cancer were treated with IMRT with doses ranging
from76 to 80Gy in 64patientswith stagesT1–T4prostate cancer and66–76Gy in 15patientswith a recurrence after prostatectomy.
The median follow-up was 20.95 months (6.1–39.6). Gastrointestinal (GI) and genitourinary (GU) posttreatment toxicities were
graded according to the RTOG Acute and Late Radiation Morbidity Scoring Criteria/Schema. Sexual toxicity was graded according
to theNational Cancer Institute’s CommonTerminology Criteria for Adverse Events (CTC 4.0).We evaluated the toxicity presented
during radiotherapy=0 months (0m), at 3 months (3m) and 6 months (6m) after completion of therapy (Acute Toxicity). Finally,
we evaluated the toxicity from 6 months of completing treatment to the last follow-up date (Late Toxicity).
Results. Grade≥2 toxicities of non-operated patients: Acute GU toxicity: 0m: 33.3%; 3m: 3.2%; 6m: 1.6%. Acute GI toxicity: 0m:
1.6%; 3m: 0%; 6m: 0%. Late GU toxicity: 1.6%. Late GI toxicity: 0%. Late sexual toxicity: 31%. Grade≥2 toxicities of operated
patients: Acute GU toxicity: 0m: 13.3%; 3m: 0%; 6m: 0%. Acute GI toxicity: 0m: 0%; 3m: 0%; 6m: 0%. Late GU toxicity: 7.1%. Late
GI toxicity: 0%. Late sexual toxicity was: 100%.
Conclusions. IMRT was feasible and sure, with low rates of serious acute toxicity and without any late grade 3–4 genitourinary or
gastrointestinal toxicity despite the delivery of high radiation dose levels. Many non-operated patients preserved erection long
term. More patients and longer follow-up are needed to conﬁrm our results.
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Introduction. Acute grade 3 toxicity is uncommon during stereotactic body radiation therapy (SBRT) for low-risk prostate cancer
(PCa) using robotic radiosurgery (Katz, 2010; Freeman, 2011).
Purpose. Single-institution single-arm prospective study in low-intermediate PCa. Endpoint: To assess acute toxicity (to
exclude>5% men have grade3 GU or any grade3 GI).
